Pages that link to "Q33999301"
Jump to navigation
Jump to search
The following pages link to Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor (Q33999301):
Displaying 41 items.
- The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats (Q21132285) (← links)
- Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents. (Q24603864) (← links)
- The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties (Q24633511) (← links)
- Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy (Q24658095) (← links)
- Triple reuptake inhibitors: the next generation of antidepressants (Q24658248) (← links)
- Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development (Q26853509) (← links)
- Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs (Q28074736) (← links)
- Triple uptake inhibitors: therapeutic potential in depression and beyond (Q28241732) (← links)
- Current investigational drugs for major depression (Q28244223) (← links)
- Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties (Q28248325) (← links)
- Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat (Q28251435) (← links)
- Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials (Q28252146) (← links)
- The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats (Q28295236) (← links)
- Assessment of Biomarkers of Drug-Induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Reuptake Inhibitor (Q28303881) (← links)
- Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs (Q28305100) (← links)
- Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters (Q28545209) (← links)
- Triple Reuptake Inhibitors: A Premise and Promise (Q28972234) (← links)
- The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. (Q34644369) (← links)
- Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template. (Q35054544) (← links)
- Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression (Q35120152) (← links)
- Rodent models of treatment-resistant depression. (Q35580361) (← links)
- Multi-modality: a new approach for the treatment of major depressive disorder (Q36896252) (← links)
- Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands (Q37020345) (← links)
- Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants (Q37071538) (← links)
- Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? (Q37158450) (← links)
- Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes (Q37460264) (← links)
- Depression and antidepressants: molecular and cellular aspects. (Q37517285) (← links)
- Catecholamine/Serotonin interactions: systems thinking for brain function and disease (Q37518766) (← links)
- Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model. (Q37552410) (← links)
- New approaches to the pharmacological management of major depressive disorder (Q37709574) (← links)
- Classical neurotransmitters and neuropeptides involved in major depression: a review (Q37768172) (← links)
- Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited (Q37891098) (← links)
- Triple reuptake inhibitors: a patent review (2006 - 2012). (Q38167327) (← links)
- An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets (Q38167857) (← links)
- Antidepressant drug development: Focus on triple monoamine reuptake inhibition (Q38260259) (← links)
- Addiction-related effects of DOV 216,303 and cocaine: A comparative study in the mouse. (Q39299851) (← links)
- Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors (Q39665539) (← links)
- Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons (Q43165318) (← links)
- Synthesis, antidepressant activity, and toxicity of the erythro/threo racemates and optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl)hexan-1-ol (Q44519902) (← links)
- Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases. (Q47720903) (← links)
- The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition (Q48371652) (← links)